Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus.
Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus.
复制标题
DOI:
10.1016/j.vaccine.2018.05.065
复制
发表时间:
2019-08
期刊:
影响因子:
5.5
通讯作者:
B. Martina;M. Smreczak;A. Orłowska;A. Marzec;P. Trębas;Jouke M. Roose;J. Żmudziński;I. Gerhauser;P. Wohlsein;W. Baumgärtner;A. Osterhaus;P. Koraka
中科院分区:
文献类型:
--
作者:
B. Martina;M. Smreczak;A. Orłowska;A. Marzec;P. Trębas;Jouke M. Roose;J. Żmudziński;I. Gerhauser;P. Wohlsein;W. Baumgärtner;A. Osterhaus;P. Koraka
Rabies is a lethal disease in humans and animals, killing approximately 60,000 people every year. Currently, there is no treatment available, except post-exposure prophylaxis (PEP) that can be administered whenever exposure to a rabid animal took place. Here we describe the beneficial effects of a combination treatment initiated at day 4 post infection, containing anti-viral drugs and immune modulators in infected mice. Combination therapy resulted in significant increase in survival time (P < 0.05) and significantly lowers viral RNA in the brain and spinal cord (P < 0.05). Furthermore, treatment influenced markers of pyroptosis and apoptosis and early inflammatory response as measured by the levels of TNF-α. Morphological lesions were absent in rabies virus infected mice with few signs of inflammation. However, these were not significant between the different groups.